The Australian Genomic Cancer Medicine Centre (AGCMC) and Molecular Screening and Therapeutics (MoST)

  • GROUP Rare Cancers
  • DATE 02/05/2022


The AGCMC is a national network of eight cancers centres – one centre in every state and territory in Australia – that delivers the Australian Genomics Cancer Medicine Program.

Details on this project

The program oversees precision oncology clinical trials and screening studies including: the Molecular Screening and Therapeutics (MoST) study; Genic Cancer Risk in the Young (RisC) study; and Surveillance study in Multi-Organ prone syndromes (SMOC+).

The primary AGCMC centres are:

  • Canberra Hospital, ACT
  • The Kinghorn Cancer Centre/Garvan Institute, NSW
  • Peter MacCallum Cancer Centre, VIC
  • Prince Alexandra Hospital, QLD
  • Royal Adelaide Hospital, SA
  • Royal Darwin Hospital, NT
  • Royal Hobart Hospital, TAS
  • Sir Charles Gairdner Hospital, WA

The MoST study performs genomic profiling to analyse the molecular characteristics of a patient’s tumour, and where possible, match them to a MoST therapeutic study (clinical trial) or other targeted therapy. Suitable patients include those aged 16 years and older with an advanced and/or metastatic sold or blood cancer with limited treatment options, and who are fit enough and willing to participate in a clinical trial. The study is targeting rare and less common cancers.

For more information visit